Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
It produces clean, measurable numbers across the documented escalation from 0.25mg through 2.4mg all within the range of a single insulin syringe
Heres what you need to know: Target Tissue: Works specifically on adipose tissue without systemic growth hormone effects or muscle tissue impact Mechanism: Activates beta-3 adrenergic receptors on fat cell membranes, triggering intracellular fat-burning cascades Primary Action: Stimulates hormone-sensitive lipase to break down stored triglycerides into free fatty acids for energy utilization Secondary Action: Inhibits lipogenic enzymes that convert excess calories into stored fat Regional Selectivity: Particularly effective on visceral (deep abdominal) and subcutaneous fat deposits with high beta-3 receptor concentration Preservation Effect: Targets fat tissue selectively without promoting muscle protein breakdown or affecting lean tissue Unique Advantage: Does not bind to growth hormone receptors, avoiding effects on IGF-1, glucose metabolism, or insulin sensitivity Research Validation: Clinical trials with 900+ participants confirmed selective fat metabolism effects with excellent safety profile The following guide provides detailed analysis of how AOD-9604 targets fat cells, from receptor binding to metabolic outcomes
Storage Refrigerate after reconstitution
But a Phase II randomised placebo-controlled hamstring-strain trial (NCT07437547) is registered, with no published results yet [8]
How do I verify the lot information for BPC-157
Increase to 0.5 mg for at least another four weeks
